Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Loomba

Showing results (411-420 of 636) with videos related to

Pageof 64
Sort By:
Hepatology (Baltimore, Md.)|January 23, 2020
Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASHRohit Loomba, Brent A Neuschwander-Tetri, Arun Sanyal, et al.
European Radiology|December 20, 2021
MR elastography in nonalcoholic fatty liver disease: inter-center and inter-analysis-method measurement reproducibility and accuracy at 3TAn Tang, Bogdan Dzyubak, Meng Yin, et al.
Open Forum Infectious Diseases|November 13, 2025
Female Sex is Protective Against MASLD With Clinically Significant Fibrosis in a Large Cross-sectional Cohort of Persons With HIVKara Wegermann, Ayako Suzuki, Elisa Sarmiento, et al.
The Lancet. Gastroenterology & Hepatology|December 15, 2022
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose studyRohit Loomba, Eric J Lawitz, Juan Pablo Frias, et al.
Gastroenterology|September 18, 2018
Factors Associated With Histologic Response in Adult Patients With Nonalcoholic SteatohepatitisRohit Loomba, Arun J Sanyal, Kris V Kowdley, et al.
Alimentary Pharmacology & Therapeutics|September 11, 2023
MEFIB-Index and MAST-Score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease-Individual participant data meta-analysesNabil Noureddin, Veeral Ajmera, Jaclyn Bergstrom, et al.
Alimentary Pharmacology & Therapeutics|October 3, 2023
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitisStephen A Harrison, Vlad Ratziu, Quentin M Anstee, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2021
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim AnalysisZobair M Younossi, Maria Stepanova, Fatema Nader, et al.
Journal of Hepatology|November 18, 2021
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE studyMary E Rinella, Jean-Francois Dufour, Quentin M Anstee, et al.
AJR. American Journal of Roentgenology|February 2, 2022
Automated CNN-Based Analysis Versus Manual Analysis for MR Elastography in Nonalcoholic Fatty Liver Disease: Intermethod Agreement and Fibrosis Stage Discriminative PerformanceGuilherme M Cunha, Timoteo I Delgado, Michael S Middleton, et al.
Pageof 64

Showing results (411-420 of 636) with videos related to

Sort By:
Pageof 64
Hepatology (Baltimore, Md.)|January 23, 2020
Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASHRohit Loomba, Brent A Neuschwander-Tetri, Arun Sanyal, et al.
European Radiology|December 20, 2021
MR elastography in nonalcoholic fatty liver disease: inter-center and inter-analysis-method measurement reproducibility and accuracy at 3TAn Tang, Bogdan Dzyubak, Meng Yin, et al.
Open Forum Infectious Diseases|November 13, 2025
Female Sex is Protective Against MASLD With Clinically Significant Fibrosis in a Large Cross-sectional Cohort of Persons With HIVKara Wegermann, Ayako Suzuki, Elisa Sarmiento, et al.
The Lancet. Gastroenterology & Hepatology|December 15, 2022
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose studyRohit Loomba, Eric J Lawitz, Juan Pablo Frias, et al.
Gastroenterology|September 18, 2018
Factors Associated With Histologic Response in Adult Patients With Nonalcoholic SteatohepatitisRohit Loomba, Arun J Sanyal, Kris V Kowdley, et al.
Alimentary Pharmacology & Therapeutics|September 11, 2023
MEFIB-Index and MAST-Score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease-Individual participant data meta-analysesNabil Noureddin, Veeral Ajmera, Jaclyn Bergstrom, et al.
Alimentary Pharmacology & Therapeutics|October 3, 2023
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitisStephen A Harrison, Vlad Ratziu, Quentin M Anstee, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2021
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim AnalysisZobair M Younossi, Maria Stepanova, Fatema Nader, et al.
Journal of Hepatology|November 18, 2021
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE studyMary E Rinella, Jean-Francois Dufour, Quentin M Anstee, et al.
AJR. American Journal of Roentgenology|February 2, 2022
Automated CNN-Based Analysis Versus Manual Analysis for MR Elastography in Nonalcoholic Fatty Liver Disease: Intermethod Agreement and Fibrosis Stage Discriminative PerformanceGuilherme M Cunha, Timoteo I Delgado, Michael S Middleton, et al.
Pageof 64